Alkermes EPS Estimate Rises 24% to $1.91 as Shares Fall 8.3%
Analysts have raised Alkermes’ 2026 EPS estimate from $1.54 to $1.91, a 24% upward revision, while shares have declined 8.3% over the past year. Year-to-date, Alkermes’ stock performance ranks against medical peers and American Well, revealing relative underperformance.
1. EPS Estimate Revision
Analysts raised Alkermes’ non-GAAP EPS forecast for fiscal 2026 from $1.54 to $1.91, reflecting improved visibility on revenue growth drivers and better operational leverage. This 24% increase stems from stronger expected uptake of existing therapies and potential contributions from late-stage pipeline candidates.
2. Share Performance and Peer Benchmarking
Over the past 12 months, Alkermes’ shares have declined 8.3%, trailing the broader medical sector’s gains. Year-to-date performance is being closely monitored against peers—including American Well—to assess relative momentum and investor sentiment toward its growth prospects.